BuzzSparks.org

ESBATech


Antibody framework therapeutics

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain...

Founded in 1998
Homepage:
Total money raised: $63M

Wagistr. 21
CH-8952 Zurich-Schlieren

CHE

Phone: 41-44-733-4900

Updated on Apr 19, 2010
ESBATech at CrunchBase
Dominik Escher Chief Executive Officer
Martin Gertsch Chief Financial Officer
Kate Bingham Investor
Past
Graham Boulnois Director

September, 2009

ESBATech was acquired by Alcon

Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG    invest.alconinc.com

August, 2008

ESBATech raised $22M in a Series B round from SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest, and VI Partners

ESBATech rounds up $22M in second round    fiercebiotech.com

August, 2006

ESBATech raised $41M in a Series B round from SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest, and VI Partners

ESBATech Closes USD 41M Series B Venture Financing    esbatech.com

1998

ESBATech was founded in 1998